🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07144761
Recruiting Not applicable

Evaluating Patient Reported Outcomes and Surgeon Satisfaction With Ziplyft™

NCT07144761 · tracked via the Priya Life Science USA tracker
Sponsor
Osheru Inc.
Phase
Not applicable
Started
2025-08
Last updated
2025-08-27

Condition(s) studied

Blepharoplasty

Investigational drug(s) / intervention(s)

Ziplyft

Ziplyft: Ziplyft™ is a Class 1, 510(k) Exempt device for removing excess unwanted eyelid skin using a novel surgical device called Ziplyft™.

Study summary

The objective of this study is to evaluate patient-reported outcomes, surgeon reported outcomes, bruising, symmetry, the success of tissue adhesive for wound closure, and case time.

Eligibility

Sex
ALL
Min age
35 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Provide signed written consent prior to participation in any study-related procedures. 2. Ability, comprehension, and willingness to follow study instructions, and likely to complete all study visits. 3. Male or female adults, ≥ 35 years old at the Preoperative Visit 4. Willing to return for required follow-up visits. 5. Subjects with excess eyelid skin are eligible to undergo the procedure in the opinion of the investigator. 6. Female subjects must be 1-year postmenopausal, surgically sterilized, or, if of childbearing potential, have a negative urine pregnancy test at the Preoperative Visit. Women of childbearing potential must use an acceptable form of contraception throughout the study. Acceptable methods include at least one of the following: intrauterine (intrauterine device), hormonal (oral, injection, patch, implant, ring), barrier with spermicide (condom, diaphragm), or abstinence. Exclusion Criteria: 1. Subjects with a current Ptosis diagnosis 2. Subjects with a history of Graves' Disease 3. Subjects with Myasthenia Gravis 4. Subjects that in the opinion of the investigator are anatomically not conducive to using devices (e.g., heavy brow, severe hollowing of the upper eyelid, history of ocular or orbital trauma). 5. Subjects that have had any previous surgery eyelid or eyebrow region. 6. Use of anticoagulation therapy, including, but not limited to Aspirin, NSAIDS, Ibuprofen within 7 days and Xarelto, Warfarin, Enoxaparin, Plavix within 3 days prior to planned study procedure. 7. Active or recent (within 3 months) tobacco user 8. Allergy to adhesive glue 9. Participation in any study of an investigational, interventional product within 30 days prior to the Preoperative Visit or at any time during the study period. 10. Pregnant or nursing females.

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
Center for Excellence in Eye Care Miami Florida Recruiting
Vance Thompson Vision Alexandria Minnesota Recruiting
Eye Care Specialists Kingston Pennsylvania Recruiting
Vance Thompson Vision Sioux Falls South Dakota Recruiting
The Eye Centers of Racine and Kenosha, LTD Kenosha Wisconsin Recruiting

More Osheru Inc. trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07144761 on ClinicalTrials.gov ↗ ← All trials in the USA